Moderna stock: Oddo BHF lifts target for Moderna stock to USD 251.00 from USD 170.00

Published on 10/21/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results come November 6, 2026. Moderna stock costs EUR 219.75 on October 21, 2026 at Lang & Schwarz, while Oddo BHF targets USD 251.

Analyst target and reporting date

Oddo BHF raised its Moderna target from USD 170.00 to USD 251.00 on October 19, 2026.
Moderna is scheduled to report third-quarter 2026 results on November 6, 2026.
Moderna stock costs EUR 219.75 at Lang & Schwarz on October 21, 2026 at 5:45 p.m. CEST.
Moderna's market capitalization is USD 98.1 billion as of October 21, 2026.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) became the subject of a higher valuation call after Oddo BHF lifted its price target from USD 170.00 to USD 251.00 on October 19, 2026, according to Fidelity. The target is 2.19 percent above Moderna's USD 245.62 Nasdaq price at 11:51 a.m. ET on October 21, 2026. At Lang & Schwarz, the stock was trading at EUR 219.75 on October 21, 2026 at 5:45 p.m. CEST.

Oddo BHF lifts the target

The change puts the Oddo BHF target above the latest US quote, but it remains one view in a divided analyst market. MarketBeat reported on October 20, 2026 that 25 brokerages held a consensus Hold rating, with seven Buys, 14 Holds and four Sells. Its average 12-month target was USD 101.45.

Stock near its yearly high

Moderna's USD 22.28 to USD 249.16 52-week range places the current US quote 1.42 percent below the high. Trading volume was 5,678,889 shares at 11:51 a.m. ET on October 21, 2026. The company's market capitalization stood at USD 98.1 billion, while its price to earnings ratio was minus 30.93.

Results date and valuation

Moderna is scheduled to report third-quarter 2026 results on November 6, 2026, according to the company's press-release page at Moderna. Its most recent reported quarter was the second quarter of 2026, when revenue reached USD 145.00 million and GAAP net loss was USD 0.8 billion, as reported by MarketBeat.

Comparison with peers

Moderna Inc.: price to earnings ratio minus 30.93, market capitalization USD 98.1 billion. BioNTech (Nasdaq, USD): up 0.42 percent, price to earnings ratio minus 12.09, market capitalization USD 23.0 billion. Gilead Sciences (Nasdaq, USD): down 2.18 percent, price to earnings ratio minus 57.36, market capitalization USD 189.8 billion. Figures are dated October 21, 2026.

What the target means for Moderna

The immediate contrast is numerical: Oddo BHF's USD 251.00 target sits above the latest USD 245.62 Nasdaq quote, while the wider consensus target of USD 101.45 is far lower. The November 6 results date gives investors the next scheduled point for testing revenue and loss trends.

The stock was trading at EUR 219.75 at Lang & Schwarz on October 21, 2026 at 5:45 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.